Nemaura Medical Inc. (NASDAQ: NMRD) Diabetes, Obesity Solutions Differentiated in Form and Function

Rhea-AI Summary

Nemaura Medical Inc. (NASDAQ: NMRD) has introduced its BEAT(R) diabetes platform, featuring the sugarBEAT(R) continuous glucose monitor (CGM) and proBEAT(TM) healthcare app. These innovations utilize AI to help patients manage diabetes effectively. With diabetes affecting 463 million individuals globally and causing approximately 3.4 million deaths annually, Nemaura aims to address this critical health issue. The company has submitted a PMA for sugarBEAT to the FDA and is actively commercializing its products in the U.S., targeting better diabetes management for patients.

Positive

• Introduction of the BEAT(R) diabetes platform.
• sugarBEAT(R) is a CE-mark-approved Class IIb medical device.
• proBEAT(TM) combines AI-driven glucose data with a digital health service.
• PMA submitted for sugarBEAT to the U.S. FDA.

Negative

• None.

NEW YORK, Sept. 24, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio -- Nemaura Medical Inc. (NASDAQ: NMRD)  announces the availability of a broadcast titled, “Healthcare Technologies Spearheading Modern Medicine Movement, Providing Hope to Throttle Diabetes, Obesity.”

To hear the AudioPressRelease, please visit The NetworkNewsAudio News Podcast.

To view the full editorial, please visit https://nnw.fm/aKQpJ.

Globally, 463 million people have diabetes. Data from the World Health Organization shows that diabetes kills about 3.4 million people worldwide each year. The actual number of deaths where diabetes is the culprit can be difficult to discern because diabetics typically grow progressively more ill, with high blood sugar damaging the heart, blood vessels, kidneys, eyes and nerves.

Nemaura Medical Inc. (NASDAQ: NMRD) has spent the last decade developing the world’s first daily-wear, noninvasive glucose sensor and integrated healthcare app. The company’s BEAT(R) diabetes platform, inclusive of sugarBEAT(R) CGM and proBEAT(TM), which combines noninvasive glucose data processed using artificial intelligence (AI) and a digital healthcare subscription service, is clearly differentiated from others in form and function.

About Nemaura Medical Inc.

Nemaura Medical is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R) and proBEAT(TM). sugarBEAT, a CE-mark-approved Class IIb medical device, is a noninvasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real-time glucose measurements and daily glucose trend data, which may help people with diabetes and prediabetes to better manage, reverse and prevent the onset of diabetes. Nemaura has submitted a PMA (premarket approval application) for sugarBEAT to the U.S. FDA. proBEAT combines noninvasive glucose data processed using artificial intelligence and a digital health-care subscription service and has been launched in the United States as a general wellness product as part of its BEAT(R) diabetes program.

For more information, please visit www.NemauraMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD.

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only).

For more information please visit https://www.NetworkNewsWire.com.

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer.

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

FAQ

What is the recent announcement by Nemaura Medical Inc. regarding diabetes management?

Nemaura Medical Inc. announced the launch of its BEAT(R) diabetes platform, which includes the sugarBEAT(R) continuous glucose monitor and proBEAT(TM) app.

How does Nemaura Medical's sugarBEAT(R) device work?

sugarBEAT(R) is a noninvasive glucose monitor that provides real-time glucose measurements and trend data to aid diabetes management.

What is the significance of the PMA submission for sugarBEAT to the FDA?

The PMA submission is crucial for gaining regulatory approval to market sugarBEAT in the U.S., potentially expanding its reach to diabetes patients.

What market needs does Nemaura Medical Inc. address with its products?

Nemaura Medical addresses the global diabetes epidemic, which affects 463 million people and causes significant health complications and deaths.